Qolamreza Razlighi, BSc MSc PhD
Primary tabs
JAD profile
Affiliation(s):
Weill Cornell Medicine
Lab URL:
Areas of Interest:
functional magnetic resonance imaging (fMRI), Alzheimer's Disease; Aging; Neuroimaging; MRI; Amyloid PET; Metabolomics; Lipidomics;
Biography & Research:
I am an Associate Professor of Neuroscience in the Department of Radiology at Weill Cornell Medicine and currently the imaging director of the Brain Health Imaging Institute. I’m also the director of the Quantitative Neuroimaging Laboratory (QNL: https://qnlab.weill.cornell.edu/) in the Weill Cornell Medicine. The QNL uses state-of-the-art multimodal neuroimage acquisition, processing and analysis to interrogate large-scale brain networks/subsystems in young subjects, normally aging subjects, and clinical populations, particularly asymptomatic Alzheimer’s disease (AD) patients. We pioneered use of the negative BOLD response (NBR) in the fMRI signal as a robust and sensitive, yet underutilized tool to detect subtle brain network dysfunction in early/asymptomatic AD. QNL is the only research group currently funded to clarify the neural, vascular, and physiological mechanisms underpinning NBR and link NBR to patterns of brain proteinopathy (Aβ and tau) and performance in specific domains of cognition. For this project, we apply NBR and other innovative structural, functional, and molecular neuroimaging methods to disentangle spatiotemporal discrepancies in AD pathologies, and propose refinement to existing hypotheses for the underlying pathophysiology of AD. To achieve these goals, we develop techniques to quantify structural and functional brain images which allow us to detect brain-based effects that are beyond the sensitivity and specificity of commonly used methods in the field. My keen interest in AD research and my expertise in neuroimage processing pipelines have so far resulted in more than twenty AD or ADRD-related publications. I am currently the PI of an AD-related R01 project and the site PI for four different AD/ADRD-related R01 projects. Finally, I am a Co-investigators in two AD-related R01 in Weill Cornell Medicine.
